Latest
Goshe Energy Storage Secures $40M From S2G as Battery Storage Becomes Critical InfrastructureGoshe Energy Storage Secures $40M From S2G as Battery Storage Becomes Critical Infrastructure|Reactor Raises $59M to Build Infrastructure for Real-Time Generative VideoReactor Raises $59M to Build Infrastructure for Real-Time Generative Video|Ôrəbella Raises Series A Led by Silas Capital as Beauty Investors Back Product-Led GrowthÔrəbella Raises Series A Led by Silas Capital as Beauty Investors Back Product-Led Growth|Corgi Raises $106M Series B1 at $2.6B Valuation to Rebuild Insurance From the Carrier UpCorgi Raises $106M Series B1 at $2.6B Valuation to Rebuild Insurance From the Carrier Up|RevEng.AI Raises $15M Series A to Verify What Software Actually ShipsRevEng.AI Raises $15M Series A to Verify What Software Actually Ships|Canals Raises $35M Series A as AI Moves Into the Operational Core of DistributionCanals Raises $35M Series A as AI Moves Into the Operational Core of Distribution|Utilidata Raises $40M as AI and Power Infrastructure ConvergeUtilidata Raises $40M as AI and Power Infrastructure Converge|NALA Secures Up to $50M as Stablecoin Payment Infrastructure Gains Institutional BackingNALA Secures Up to $50M as Stablecoin Payment Infrastructure Gains Institutional Backing|Saris Raises $28.8M Series A to Expand Agentic AI for Banking OperationsSaris Raises $28.8M Series A to Expand Agentic AI for Banking Operations|Modiqo Raises $3M Pre-Seed to Solve AI's Most Expensive Memory ProblemModiqo Raises $3M Pre-Seed to Solve AI's Most Expensive Memory Problem|Goshe Energy Storage Secures $40M From S2G as Battery Storage Becomes Critical InfrastructureGoshe Energy Storage Secures $40M From S2G as Battery Storage Becomes Critical Infrastructure|Reactor Raises $59M to Build Infrastructure for Real-Time Generative VideoReactor Raises $59M to Build Infrastructure for Real-Time Generative Video|Ôrəbella Raises Series A Led by Silas Capital as Beauty Investors Back Product-Led GrowthÔrəbella Raises Series A Led by Silas Capital as Beauty Investors Back Product-Led Growth|Corgi Raises $106M Series B1 at $2.6B Valuation to Rebuild Insurance From the Carrier UpCorgi Raises $106M Series B1 at $2.6B Valuation to Rebuild Insurance From the Carrier Up|RevEng.AI Raises $15M Series A to Verify What Software Actually ShipsRevEng.AI Raises $15M Series A to Verify What Software Actually Ships|Canals Raises $35M Series A as AI Moves Into the Operational Core of DistributionCanals Raises $35M Series A as AI Moves Into the Operational Core of Distribution|Utilidata Raises $40M as AI and Power Infrastructure ConvergeUtilidata Raises $40M as AI and Power Infrastructure Converge|NALA Secures Up to $50M as Stablecoin Payment Infrastructure Gains Institutional BackingNALA Secures Up to $50M as Stablecoin Payment Infrastructure Gains Institutional Backing|Saris Raises $28.8M Series A to Expand Agentic AI for Banking OperationsSaris Raises $28.8M Series A to Expand Agentic AI for Banking Operations|Modiqo Raises $3M Pre-Seed to Solve AI's Most Expensive Memory ProblemModiqo Raises $3M Pre-Seed to Solve AI's Most Expensive Memory Problem
Back to articles
•

EpiFrontier Therapeutics Secures Up to $32M Non-Dilutive Funding to Advance Beta Globin Therapies

EpiFrontier Therapeutics moves like a company that already knows where the finish line is, they’re just deciding how fast to get there. Out of Pennington, New Jersey, with roots running deep through Tokyo’s research corridors, EpiFrontier Therapeutics secured up to $32M in non-dilutive funding from the Japan Agency for Medical Research and Development. Not equity. Not dilution. Just belief backed by a government that doesn’t throw darts, it funds outcomes.

Bruce Goldsmith (CEO) is steering this one, and the play here isn’t noise, it’s precision. The science traces back over a decade through RIKEN and the Tokyo University of Pharmacy and Life Sciences. We’re talking about a discovery engine that screened roughly 140,000 compounds, then refined the signal through structure-based design and over 1,000 synthesized iterations. That’s not a startup origin story, that’s a filtration system for truth.

At the center is EPF-001, a small molecule with a very specific job. It inhibits G9a, nudging the body to produce more fetal hemoglobin. For patients with sickle cell disease and beta thalassemia, that shift isn’t academic, it’s oxygen, time, and margin. First-in-class gets thrown around casually these days. This one actually had to earn it.

The funding lands through AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem, which is a long name for a very simple idea. Back the science that has a shot at changing lives, then give it the runway to prove it. No cap table gymnastics, no signaling theater, just fuel for Phase 2 clinical development and a path into patient populations that actually need it.

UTEC is already in the mix, with Azusa Shiohara on the board, which tells you this wasn’t stumbled into. This was built, pressure-tested, and positioned before most people even knew where to look.

The real takeaway sits beneath the headline number. When your foundation is rooted in serious science, when your IP is locked in from institutions that don’t miss often, and when your development path is mapped across global clinical networks, capital starts to behave differently around you. It becomes less about chasing and more about alignment.

Epifrontiertx

Epifrontiertx

EPF-001 small-molecule G9a inhibitor for sickle cell disease and beta thalassemia by inducing fetal hemoglobin; ~140K compounds screened from RIKEN heritage

  • Pennington, NJ
Website

Key Executives

  • Bruce Goldsmith (CEO)

Related Articles

Trending

View all posts